Chyme Reinfusion Included in NZ NIFRS Clinical Guidelines

Source：The Insides Company Limited

On：Wednesday, 11 January 2023

Organisation：The Insides Company Limited

Chyme reinfusion therapy has now been included in the New Zealand National Failure & Rehabilitation Service (NZ NIFRS) clinical guidelines.

The NZ NIFRS clinical guidelines for chyme reinfusion links to The Insides Company Training Hub where available content includes guidance around establishing, maintaining and monitoring chyme reinfusion therapy using The Insides System, an automated chyme reinfusion solution for reinfusing the intestinal losses of patients with a high-output fistula or enterostomy.

Chyme reinfusion is an established technique recommended by the international societies ASPEN and ESPEN for the nutrition of Type 2 Intestinal Failure patients (Klek et al., 2016).

Chyme reinfusion enables：

‍

• Reduction in fistula/enterostomy output (Picot et al., 2017)
• Improved nutrition and weight gain (Sharma et al., 2019)
• Reduced complications associated with parenteral nutrition (Sharma et al., 2019)
• Significant health economic savings (Thibault et al., 2016)

Clinicians will be able to gain access to the chyme reinfusion clinical guidelines via the link below.

(link)

About The Insides Company

The Insides Company Limited is a leading provider of automated chyme reinfusion solutions for the therapeutic treatment of intestinal failure that has resulted from either a high-output enterocutaneous fistula or enterostomy.

Contact

The Insides Company

Garth Sutherland, CEO

Phone：+64 9 887 9309

Email：sales@theinside.co

‍